Two Ongoing Clinical Trials of IPI-145 for Hematologic Malignancies
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.
DUO
- DUO is a randomized, phase III trial comparing IPI-145 to ofatumumab for patients with relapsed or refractory CLL or SLL.
- Ofatumumab is a CD20-directed cytolytic monoclonal antibody approved for the treatment of CLL.
- Patients in this trial are randomized 1:1 and are able to cross over.
DYNAMO
- DYNAMO is a single-arm, phase II trial of patients with non-Hodgkin lymphoma that are no longer responding to rituximab or chemotherapy.
- There is currently no established therapy for this group of patients.
<<<
Novel Approaches Focus on Limiting Toxicity in Older Patients with ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
